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Background: Non-small cell lung cancer (NSCLC) is the leading cause of cancer-related death worldwide. Pemetrexed, a
multi-target folate antagonist, has demonstrated efficacy in NSCLC histological subtypes characterized by low
thymidylate synthase (TS) expression. Among many other potential targets, histone deacetylase inhibitors (HDACi)
modulate TS expression, potentially sensitizing to the cytotoxic action of anti-cancer drugs that target the folate
pathway, such as pemetrexed. Since high levels of TS have been linked to clinical resistance to pemetrexed in NSCLC,
herein we investigated the molecular and functional effects of combined pemetrexed and ITF2357, a pan-HDACi
currently in clinical trials as an anti-cancer agent.
Results: In NSCLC cell lines, HDAC inhibition by ITF2357 induced histone and tubulin acetylation and downregulated
TS expression at the mRNA and protein level. In combination experiments in vitro ITF2357 and pemetrexed
demonstrated sequence-dependent synergistic growth-inhibitory effects, with the sequence pemetrexed followed by
ITF2357 inducing a strikingly synergistic reduction in cell viability and induction of both apoptosis and autophagy in all
cell line models tested, encompassing both adenocarcinoma and squamous cell carcinoma. Conversely, simultaneous
administration of both drugs achieved frankly antagonistic effects, while the sequence of ITF2357 followed by pemetrexed
had additive to slightly synergistic growth-inhibitory effects only in certain cell lines. Similarly, highly synergistic growth
inhibition was also observed in patient-derived lung cancer stem cells (LCSC) exposed to pemetrexed followed by
ITF2357. In terms of molecular mechanisms of interaction, the synergistic growth-inhibitory effects observed were only
partially related to TS modulation by ITF2357, as genetic silencing of TS expression potentiated growth inhibition by either
pemetrexed or ITF2357 and, to a lesser extent, by their sequential combination. Genetic and pharmacological
approaches provided an interesting link between the autophagic and apoptotic pathways, and showed that sequential
pemetrexed/ITF2357 causes a toxic form of autophagy with consequent activation of a caspase-dependent apoptotic
program. In vivo experiments in NSCLC xenografts confirmed that sequential pemetrexed/ITF2357 is feasible and results
in increased inhibition of tumor growth and increased mice survival.
Conclusions: Overall, these data provide a strong rationale for the clinical development of sequential schedules
employing pemetrexed followed by HDACi in NSCLC.
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Lung cancer is the most common cause of cancer-related
death worldwide, with non-small cell lung cancer (NSCLC)
accounting for approximately 80% of all lung cancers [1,2].
Despite progresses in systemic treatment, only a small
proportion of patients diagnosed with metastatic disease
survive over 5 years. Most patients relapse within 1 year
of starting first-line treatment mainly due to intrinsic or
acquired resistance to chemotherapy [3]. Pemetrexed
(Alimta, Eli Lilly and Company), a multi-target folate
antagonist, has recently become the cornerstone of treat-
ment for non-squamous carcinoma of the lung [4]. The
selective sensitivity of non-squamous NSCLC to peme-
trexed cytotoxicity is thought to be related to the levels of
expression of thymidylate synthase (TS), an essential
enzyme for the de novo synthesis of thymidylate and sub-
sequently DNA synthesis, and one of the main intracellu-
lar molecular targets of pemetrexed; indeed, elevated TS
expression has been proposed as a biomarker of resistance
to pemetrexed-based chemotherapy [5-13].
Recently, it has been proposed that patients with
NSCLC might benefit from combined treatment with epi-
genetic drugs [14,15]. In this context, histone deacetylase
inhibitors (HDACi) represent a promising class of antitu-
mor agents, developed to reverse the silencing of critical
regulatory pathways [16,17]. Indeed, the cellular response
to treatment with HDACi shows pleiotropic effects involv-
ing cell cycle arrest, induction of apoptosis/autophagy and
differentiation, modulation of microtubule function, DNA
repair, and angiogenesis [18-20]. Based on their ability to
activate the apoptotic and autophagic pathways, HDACi
may have interest in combination with conventional
chemotherapeutic agents to enhance tumor cell chemo-
sensitivity [14,18,21,22]. HDACi have been demonstrated
to regulate the expression of several genes and proteins
including TS. Transcriptional regulation of TS may be
attributed to Rb-E2F1 pathway modulation by p21waf1⁄cip1
up-regulation via its promoter histone acetylation by
HDACi [23]. Thus, the effects of drugs that critically rely
on TS inhibition to exert their cytotoxic action, such as 5-
Fluorouracil (5FU), raltitrexed, and pemetrexed [23,24]
can be potentially increased by HDACi [25,26].
Both apoptosis, a genetically programmed cell death
pathway regulated by the complex interaction between
anti- and pro-apoptotic proteins, and autophagy, a
complex cellular process with a multifaceted role in
cell death, have been implicated in the response to
antineoplastic treatments [27-29]. Under conditions of
limited stress, such as starvation, autophagy promotes
cell survival by degrading and recycling long-lived
proteins and cellular components [30,31]; however,
when the cell is exposed to prolonged or excessive con-
ditions of stress, autophagy has been shown to result
in cell death by self-digestion [32].In this study we evaluated the antitumor efficacy and
the molecular mechanisms of action of ITF2357, a pan-
HDACi [33-36], in combination with pemetrexed, using
in vitro and in vivo models of NSCLC and patient derived
lung cancer stem-like cells (LCSC). ITF2357 potentiated
pemetrexed cytotoxic activity in a sequence-dependent
manner: indeed, the combination of pemetrexed followed
by ITF2357 showed a highly synergistic interaction
in vitro in both NSCLC and LCSC cells. The observed
decrease in cell viability was due to activation of both
apoptosis and autophagy, which were interconnected in
the synergistic loss of cell viability induced by sequential
pemetrexed/ITF2357.Methods
Cell cultures, plasmids, and transfection
Human NSCLC established cell lines (H1299, H460,
A549, H1650, Calu-1) were cultured in 10% inactivated
foetal bovine serum (HyClone, Termoscientific, South
Logan, UT) in RPMI medium (Invitrogen, Carlsbad,
CA). H1299 short hairpin (sh) Beclin1, shControl,
EGFP-LC3B and ptf-LC3 stable clones were generated
as previously described [37] and cultured in the
presence of geneticin (800 μg/ml, Sigma-Aldrich, St.
Louis, MO).
Patient-derived LCSC18, LCSC36, LCSC136 and
LCSC143 cell lines were isolated as described [38] and cul-
tured in serum-free medium containing 50 μg/ml insulin
(Sigma-Aldrich), 100 μg/ml apo-transferrin (Sigma-
Aldrich), 10 μg/ml putrescine (Sigma-Aldrich), 0.03 μM
sodium selenite (Sigma-Aldrich), 2 μM progesterone
(Sigma-Aldrich), 0.6% glucose (Sigma-Aldrich), 5mM
HEPES (Euroclone, Pero, Italy), 0.1% sodium bi-
carbonate (Euroclone), 0.4% BSA (PAA Healthcare,
Milan, Italy), glutamine (Euroclone), and antibiotics
(Euroclone), dissolved in DMEM–F12 medium (Invitro-
gen) and supplemented with 20 ng/ml EGF (Peprotech,
Princeton, NJ) and 10 ng/ml bFGF (Peprotech). Flasks
non-treated for tissue culture were used to reduce cell ad-
herence and support growth as undifferentiated tumor
spheres.
Pooled small interfering RNA (siRNA) oligonucleotides
against TS and ATG7 were purchased from Dharmacon
RNA Technologies (siGENOME SMART pool, Lafayette,
Colorado). For siRNA transfection, cells were seeded and
after 24 h transfected with 100 nM pooled oligonucleo-
tides mixture by using Lipofectamine2000 (Invitrogen) fol-
lowing manufacturer’s protocol. 24 h after transfection,
media were removed and cells were treated with Peme-
trexed (Alimta, formerly LY231514, Eli Lilly and Com-
pany) and ITF2357 (Givinostat, Italfarmaco) alone or in
combination. Gene silencing efficacy by siRNA was
assessed by Western blot or qRT-PCR analyses.
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Cells were treated with ITF2357 and pemetrexed, either
alone or in combination, as follows: (a) ITF2357; (b)
pemetrexed; (c) ITF2357 and pemetrexed, simultaneously;
(d) ITF2357 followed by pemetrexed; (e) pemetrexed
followed by ITF2357. Both detached and adherent cells
were collected, and differentially processed according to
analyses performed.
3-Methyladenine (3MA, 1mM) (Enzo Life Science,
Plymouth Meeting, PA, USA), and the pan-caspase in-
hibitor zVAD-fmk (zVAD, 50μM, Sigma-Aldrich) were
dissolved in DMSO. Chloroquine diphosphate (CQ, 25μM,
Sigma-Aldrich) was dissolved in water.
Assessment of cell viability
The inhibitory effect of different drugs was assessed
following manufacturer’s protocol on i) NSCLC cell growth
by measuring 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltet-
razolium bromide inner salt (MTT, Sigma-Aldrich) dye
absorbance of cells, and ii) LCSC cell growth by quantita-
tion of the ATP present in metabolically active cells using
CellTiter-Glo® Luminescent (Promega, Southampton, UK).
Data were analyzed by the Chou-Talaly method (CalcuSyn
software, Biosoft, Cambridge) to determine the combin-
ation index (CI), a well-established index of the interaction
between two drugs. CI values of <1, =1, and >1 indicate
synergistic, additive, and antagonistic effects, respectively.
Flow cytometric analysis
Flow cytometric analysis (BD Accuri™ C6, BD biosciences)
was performed to evaluate cell cycle distribution by propi-
dium iodide (PI) staining, apoptosis by AnnexinV-FITC/
PI staining, and to detect acidic vesicular organelles
(AVOs) by acridine orange staining, as previously described
[39,40]. Active Caspase-3 Apoptosis Kit (BD biosciences)
was used to detect the heterodimer of 17 and 12 kDa
subunits, which is derived from the pro-enzyme.
Analysis of autophagy
Cells grown on glass coverslips were fixed in 2% formalde-
hyde for 10 minutes at room temperature. Detection of
autophagosomal structures was performed by fluorescence
microscopy observing LC3B puncta in EGFP-LC3B
expressing cells [41]. Autophagic flux was analyzed by
fluorescence microscopy monitoring the distribution and
alteration of mRFP-GFP-LC3B fluorescent signals [41].
Typically, at least 200 cells were counted, and cells with
more than 10 puncta were considered autophagy positive.
Images were scanned under a × 63 oil immersion ob-
jective and, to avoid bleed-through effects, each fluores-
cent signal was scanned independently by using a Leica
DMIRE2 microscope equipped with a Leica DFC
350FX camera, elaborated by a Leica FW4000 decon-
volution software (Leica, Solms, Germany) and processed using Adobe PhotoShop software to adjust image
brightness and contrast.
Quantitative real-time polymerase chain reaction
(qRT-PCR)
Total RNA was extracted from in vitro cultured cells using
a Qiagen RNeasy Mini kit (Qiagen) according to the manu-
facturer’s instructions. Reverse transcription was performed
using RevertAid Reverse Transcriptase (Thermo Scien
tific). qRT-PCR was performed using a Gene-Amp 5700
sequence detection system (Applied Biosystems, Foster
City, CA, USA). The mRNA levels were normalized using
glyceraldehyde 3-phosphate dehydrogenase (GAPDH), a
housekeeping gene that was used as the internal control,
because its expression has been demonstrated to remain
stable during the protocol. The following primers were
used: TS Forward: GCGCTACAGCCTGAGAGATG, TS
Reverse: TGCCCCAAAATGCCTCCACT, GAPDH For-
ward: TCCCTGAGCTGAACGGGAAG, GAPDH Reverse:
GGAGGAGTGGGTGTCGCTGT.
qRT-PCR was also performed by using tumor thick
sections (10 mm) for RNA extraction. The sections were
serial to other 4 mm-thick sections, from the same
formalin-fixed paraffin embedded tumor block, used for
H&E staining, to select appropriate neoplastic areas and
for TS immunohistochemistry. The 10 μm-thick sections
were dried overnight at 56°C, de-paraffinated and
stained with Nuclear Fast Red solution (Sigma-Aldrich),
then rehydrated through graded alcohols and dissected
using a scalpel. RNA isolation and retrotranscription were
performed as previously reported [42]. An ABI PRISM
7900HT Sequence Detection System (Life Technologies,
Applied Biosystems Division, Carlsbad, CA, USA) in 384-
wells plate was used. All qPCR mixtures contained 1μl of
cDNA template (approximately 40 ng of retrotranscribed
total RNA) diluted in 9 μl of distilled-sterile water, 1200 nM
of each primer, 200 nM of internal probe and TaqMan
Gene Expression Master Mix (Life Technologies) to a final
volume of 20 μl. The sequences of primers and probes used
for qPCR analyses were previously published [42].
Cycling conditions were 50°C for 2 minutes, 95°C for 10
minutes followed by 46 cycles at 95°C for 15 seconds and
60°C for 1 minute. Baseline and threshold for cycle thresh-
old calculation were set manually with ABI Prism SDS 2.4
Software. A mixture containing Human Total RNA
(Stratagene, La Jolla, CA) was used as control calibrator on
each plate. β-actin was used as internal reference gene. The
fold change in gene expression levels, expressed in unitless
values, was evaluated using the 2–ΔΔCt method [43].
Western blot analysis
Total protein extracts were fractionated by SDS-PAGE,
transferred to a nitrocellulose filter and subjected to
immunoblot assay. Immunodetection was performed using
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Billerica, MA), TS (ab58287, Abcam), p62/SQTSM1
(Santa Cruz Biotechnology, Santa Cruz, CA), HSP72/73
(Calbiochem, San Diego, CA), LC3B and acetyl-α-tubulin
(K40, Sigma-Aldrich), ATG7 (Millipore), caspases 3 and
PARP (Santa Cruz). Anti-mouse or anti-rabbit immuno-
globulin G (IgG)-horseradish peroxidase conjugated anti-
bodies (Cell Signaling, Amersham Biosciences, Freiburg,
Germany) were used as secondary antibodies at 1:10000
dilution. Antibody binding was visualized by enhanced
chemiluminescence method (Amersham Biosciences) ac-
cording to manufacturer’s specification and recorded on
autoradiographic film (Amersham Biosciences). Developed
films were acquired using GS-700 Imaging Densitometer
(Biorad Laboratories, Hercules, CA) and processed with
Adobe PhotoShop software. Densitometric evaluation was
performed using Molecular Analyst Software (Biorad) and
normalized with relative controls depending on the analysis.
In vivo experiments
To evaluate the effect of different treatments on in vivo
tumor growth, 5 × 106 cells were injected intramuscularly
into 6-8 week-old female immunodeficient athymic mice
(10 for each group). Weekly intraperitoneal treatment with
pemetrexed (1000 mg/Kg), and oral administration with
ITF2357 (100 mg/Kg) every 24 h for 4 days started when
tumors were palpable (about 7 days after cell injection),
and stopped when the animals were sacrificed. Animals
were observed daily and tumor volume (mm3) calculated as
length × width2 × π/6. Mice survival was calculated by
euthanizing the animals when the tumors reached 2.5 g.
The experiments were repeated twice. All procedures
involving animals and their care were authorized and
certified by the decree n. 67/97A of the Italian Minister of
Health and protocol 2560/97 of the Rome Health Service
Unit (ASL – RMB).
Statistics
Experiments were replicated three times, unless other-
wise indicated, and the data were expressed as mean ±
standard deviation (SD) or mean ± standard error (SEM).
Differences between groups were analyzed with a two-
sided paired or unpaired t test and were considered to
be statistically significant for p < 0.05.
Results
ITF2357 downregulates TS expression and enhances
pemetrexed cytotoxicity in NSCLC models
We first investigated in vitro effects of the HDAC
inhibitor ITF2357 in four NSCLC cell lines. ITF2357
dose-dependently inhibited the growth of all cell lines
tested, with IC50 values ranging from 3 to 20 μM after 72 h
of drug exposure (Figure 1A). Increased acetylation of both
histone H3 and α-tubulin was observed by Western blotanalysis after 24 h treatment with 0.5 and 1 μM ITF2357
in all cell lines tested (Figure 1B).
Next, we examined the levels of TS mRNA and protein
expression following ITF2357 treatment. ITF2357 (0.5 and
1 μM) significantly reduced TS expression at both the
mRNA (Figure 1C) and protein (Figure 1B) level in all
four NSCLC cell lines.
Since TS expression may affect sensitivity to pemetrexed
[13], we assessed whether ITF2357 could modulate peme-
trexed cytotoxicity. To this purpose, combination studies
were performed using a fixed-ratio experimental design
(1:1) in H1299, A549 and Calu-1 cell lines using three
different schedules: simultaneous treatment with the two
drugs, ITF2357 followed by pemetrexed, and pemetrexed
followed by ITF2357. As shown by growth inhibition
curves (Additional file 1: Figure S1A) and analysis of drug
interactions (Additional file 1: Figure S1B), simultaneous
treatment with equipotent doses of pemetrexed and
ITF2357 for 72h resulted in an antagonistic effect (H1299,
CI = 1.7; A549, CI = 2.97, Calu-1: CI = 7.26) in all cell lines
analyzed. The sequence of ITF2357 followed by peme-
trexed had synergistic growth inhibitory effects in H1299
and Calu-1 cells (H1299: CI = 0.54; Calu-1: CI = 0.37),
whereas it had an effect comparable to that of ITF2357
alone in A549 cells (Additional file 1: Figure S1A,B). Of
note, the sequence of pemetrexed followed by ITF2357
was the most effective, with strikingly synergistic drug
interactions and CI values < <1 in all cell lines studied:
H1299, CI = 0.21; A549, CI = 0.15; Calu-1, CI = 0.02
(Figure 1D,E). A strong growth-inhibitory effect in vitro
and a synergistic drug interaction was also observed in
three other NSCLC cell lines (H1975, CI = 0.21; H460,
CI = 0.12; H1650 CI = 0.59; Additional file 2: Figure S2A,B)
treated with this schedule.Sequential treatment with ITF2357 enhances pemetrexed-
induced apoptosis in NSCLC models
Next, we explored the putative mechanisms of synergistic
growth-inhibitory interactions induced by pemetrexed
followed by ITF2357 in the A549 and H1299 representa-
tive cell lines. As shown in Figure 2A, less than 10% of
cells with sub-G1 DNA content were detected after either
drug alone; in contrast, when cells were exposed to peme-
trexed followed by increasing concentrations of ITF2357,
the percentage of sub-G1 cells dose-dependently increased
up to 32% and 23% in A549 and H1299 cells, respectively.
Apoptosis induction was confirmed by cytofluorimetric
analysis of AnnexinV/PI staining (Figure 2B). Conversely,
combined treatment with ITF2357 given simultaneously or
before pemetrexed did not increase apoptosis induction in
H1299 cells, as compared with treatment with individual
drugs (data not shown). Consistently, pro-caspase 3 activa-
tion was observed in H1299 cells exposed to pemetrexed
Figure 1 (See legend on next page.)
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Figure 1 Cytotoxic synergism of pemetrexed followed by ITF2357 in human NSCLC cell lines. (A) Analysis of cell viability by MTT assay in
the indicated NSCLC cell lines treated for 72 h with increasing concentrations of ITF2357. (B) Western blot analysis of acetylated histone H3 (Ac-H3),
acetylated α-Tubulin (Ac-Tubulin) and TS protein expression in total cell lysates from the indicated NSCLC cell lines treated with increasing concentration of
ITF2357 for 24 h. HSP72/73 expression was used as loading and transferring control. Western blots representative of two independent experiments with
similar results are shown. (C) TS mRNA expression by quantitative RT-PCR in NSCLC cells treated with increasing concentration of ITF2357 for 24 h. Results
are presented as the mean ± SD of two independent experiments. p values were calculated between control and treated cells (*p < 0.05). (D) Analysis of
cell viability by MTT assay in the indicated NSCLC cell lines treated with ITF2357 and pemetrexed (Pem, drug ratio 1:1) alone or in combination. Treatment
with pemetrexed for 24 h was followed by treatment with ITF2357 for 48 h. (●, ITF2357; ■, pemetrexed;▲, combination). (A,D) The results are reported as
“viability of drug-treated cells/viability of control cells” × 100 and represent the mean ± SD of three independent experiments performed in triplicate.
(E) Interaction between pemetrexed followed by ITF2357 treatment evaluated on the basis of the Combination Index, which is plotted against fractional
growth inhibition. Data are means of triplicates from experiments that were repeated three times.
Figure 2 Combination treatment with pemetrexed followed by ITF2357 leads to apoptosis induction in human NSCLC cell lines.
Flow cytometric analysis of (A) cell cycle distribution by PI staining, and (B) apoptotic cells by AnnexinV/PI staining in A549 and H1299 cell lines
exposed to pemetrexed (Pem, 0.1 μM) or ITF2357 (from 0.1 to 1 μM) given alone or in combination (24 h pemetrexed followed by 48 h ITF2357).
(A) The percentage of cells in sub-G1 and in the different cell cycle phases is shown. Where not reported, the percentage of cells in sub-G1 phase was less
than 10%. Each panel is representative of three independent experiments with comparable results. (B) The percentage of AnnexinV+/PI- (early apoptotic
cells, lower right), AnnexinV+/PI + (late apoptotic cells, upper right), AnnexinV-/PI- (viable cells, lower left) and AnnexinV-/PI + (necrotic cells, upper left), cells
is shown.
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drug alone (Additional file 3: Figure S3F).
We also analyzed the effect of each agent, alone or in
combination, on TS mRNA and protein expression in
the H1299 cell line. After exposure to pemetrexed (24 h)
followed by wash out of the drug (24 h), TS expression
was upregulated at both mRNA (Figure 3A) and protein
(Figure 3B) levels; conversely, ITF2357 profoundly down-
regulated TS mRNA and protein expression (Figure 1B,C
and Figure 3A,B) and, in combination treatment, com-
pletely prevented pemetrexed-induced TS upregulation,
when ITF2357 was used at high doses (Figure 3A,B). To
determine if ITF2357-induced TS modulation is causally
involved in the observed synergism, we next evaluated
whether TS knockdown by a specific siRNA (Additional
file 3: Figure S3A) affects ITF2357/pemetrexed-mediated
apoptosis in H1299 cells. TS silencing sensitized cells to
treatment with both agents, alone or in combination, in
terms of both viability (Figure 3C) reduction and apoptosis
induction (Figure 3D).
Sequential treatment with pemetrexed followed by
ITF2357 induces autophagy in NSCLC models
To assess the role of apoptosis in the growth inhibitory syn-
ergism observed with pemetrexed followed by ITF2357, we
performed experiments in the absence or presence of the
pan-caspase inhibitor zVAD. First, we analyzed apoptotic
and non-apoptotic populations for active caspase-3, using
A549 cells (Additional file 2: Figure S2C). We found that
untreated, as well as pemetrexed-treated cells were primar-
ily negative for the presence of active caspase-3, whereas
about 20% of ITF2357 treated cells were positive for active
caspase-3 staining. This percentage increased up to about
36% when cells were exposed to combined treatment and,
as expected, the pan-caspase inhibitor zVAD completely
inhibited caspase-3 activation. Similar results were observed
in H1299 cells (data not shown). zVAD also almost
completely inhibited apoptosis induced by combined treat-
ment in H1299 cells, as demonstrated by the percentage of
AnnexinV positive cells (Figure 3F), but had very limited,
albeit statistically significant, effects on loss of viability
induced by the combination (Figure 3E). Similar results
were obtained with A549 cells (data not shown).
Since both HDACi and pemetrexed can induce autoph-
agic flux [28,44,45], we investigated autophagy as a poten-
tially alternative mode of cell death activated by combined
pemetrexed followed by ITF2357. As shown in Figure 4A,
vital staining of H1299 and A549 cells with acridine or-
ange showed prominent AVOs formation after exposure
to pemetrexed followed by ITF2357, while a much lower
percentage of AVOs positive cells was observed after treat-
ment with individual drugs. Autophagy induction was fur-
ther confirmed by analysis of microtubule associated
protein I light chain 3 (LC3) redistribution in H1299 cellsstably expressing an EGFP-LC3B fusion protein. As shown
in Figure 4B,D, diffuse cytoplasmic distribution of green
fluorescence was observed in both control and
pemetrexed-treated cells, whereas an increase in the
characteristic redistribution of EGFP-LC3B into punctate
vesicular structures was observed in cells exposed to
ITF2357 and, to a much greater extent, in cells exposed to
sequential pemetrexed followed by ITF2357.
To obtain clearer results about the effect of drug combin-
ation on autophagic flux, we analysed the distribution and
alteration of mRFP-GFP-LC3B fluorescent signals using
H1299 cells stably expressing mRFP-EGFP-LC3 reporter
(H1299/ptf-LC3) [37,41] (Figure 4C,D). As GFP but
not mRFP fluorescence is lost in acidic compartments,
mRFP-GFP-LC3B labels nonacidic autophagosomes as
yellow fluorescence (positive for both green and red)
but acidic autophagolysosomes as red fluorescence
only [41]. The increase of red fluorescence observed
under ITF2357 and combination treatment indicates that
autolysosome maturation proceeds normally. By contrast,
as expected a prominent increase in the yellow fluores-
cence vesicles was observed in CQ-treated cells, indicating
incomplete/impaired autophagosome maturation into
lysosome (Additional file 4: Figure S4).
Consistent with these data, Western blot analysis
performed in H1299 cells showed increased processing of
the membrane-bound form of microtubule-associated
protein LC3BII, decreased p62/SQTSM1 protein levels,
and increased Beclin1 expression in ITF2357-treated cells,
particularly after sequential exposure to pemetrexed
followed by ITF2357 (Figure 4E). Conversely, no changes
in ATG7 expression were observed after single and com-
bined drug treatment (Figure 4E).
Hierarchical activation of autophagy and apoptosis in
response to sequential treatment with pemetrexed
followed by ITF2357
As shown in Figures 2, 3, and 4, exposure of NSCLC cell
lines to pemetrexed followed by ITF2357 induced both apop-
tosis and autophagy; moreover pharmacological caspase in-
hibition by zVAD completely abolished caspase 3 activation
(Additional file 2: Figure S2) and apoptosis induction
(Figure 3F), but only marginally affected cell viability
(Figure 3E). Most importantly, zVAD had no effect on AVOs
accumulation induced by drug combination (Figure 5A).
Since autophagy has been implicated in both inhibition
and promotion of cell survival [46,47], we investigated
whether a functional relationship exists between apoptosis
and autophagy, by silencing the expression of proteins
acting at the early steps of autophagy, such as Beclin1 or
ATG7, as a genetic approach to inhibit autophagy [41].
Selective knockdown of Beclin1 (Additional file 3:
Figure S3B) substantially inhibited both AVOs formation
(Figure 5A) and apoptosis induction, as measured by
Figure 3 (See legend on next page.)
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Figure 3 Silencing of TS expression in H1299 cells enhances the apoptotic effect of pemetrexed and ITF2357 alone or in combination.
Analysis of TS mRNA (A) and protein (B) expression evaluated respectively, by quantitative RT-PCR (A) or Western blot analysis (B) in H1299 cells
exposed to pemetrexed (Pem, 0.1 μM) or ITF2357 (from 0.1 to 1 μM) alone or in combination (24 h pemetrexed followed by 24 h ITF2357). (A) Results
are presented as the mean ± SEM of 2 independent experiments. p values were calculated between untreated and treated cells (*p < 0.05). (B) HSP72/
73 expression was used as loading and transferring control. Western blot representative of two independent experiments with similar results is shown.
Analysis of (C) viable cells evaluated by CellTitleGLO, and (D) apoptotic cells evaluated by AnnexinV/PI staining in HI299 cells transiently transfected
with control RNA interference (H1299/Cont) or RNA interference directed against TS (H1299/siTS) exposed to pemetrexed (0.1 μM) or ITF2357 (1 μM)
alone or in combination (24 h pemetrexed followed by 48 h ITF2357). Analysis of (E) viable cells evaluated by CellTitleGLO and (E) apoptotic cells
evaluated by AnnexinV/PI staining in HI299 exposed to ITF2357 or pemetrexed as reported in C) in absence or presence of the pan-caspase inhibitor
zVAD (50 μM). (C-F) p values were calculated between untreated and treated cells (*p < 0.05). The results represent the mean ± SD of three
independent experiments.
Del Bufalo et al. Molecular Cancer 2014, 13:230 Page 9 of 16
http://www.molecular-cancer.com/content/13/1/230AnnexinV binding (Figure 5B), particularly in response to
combined pemetrexed/ITF2357 treatment. Moreover,
Western blot analysis performed in H1299/shBeclin1 cells
exposed to different treatment with or without low con-
centrations of CQ, a late stage autophagic inhibitor,
showed only slightly processing of LC3-II protein and p62
degradation in cells exposed to both single or combination
treatment when compared to untreated cells, indicating
that autophagic flux is regulated upstream by Beclin1.
Of note, the addition of low doses of CQ dramatically
promotes the LC3-II protein accumulation and recov-
ery of p62 levels (Additional file 4: Figure S4B). Inhib-
ition of both AVOs formation (Figure 5A) and
apoptosis induction (Figure 5B), in response to com-
bined pemetrexed/ITF2357 treatment was also ob-
served following ATG7 silencing (Additional file 3:
Figure S3C). Upon combination treatment selective
knockdown of Beclin1 resulted in a decreased per-
centage of cells positive for active caspase-3 staining,
when compared to control-transfected H1299 cells
(Additional file 3: Figure S3F). Moreover, residual cells
positive for active caspase-3 staining in H1299/shBe-
clin1 cells completely disappeared in the presence of
pan-caspase inhibitor (data not shown). As a result,
knockdown of either Beclin1 or ATG7 prevented the
cytotoxic interaction between ITF2357 and pemetrexed,
restoring the viability of cells exposed to the combin-
ation to levels comparable to those of cells exposed to
ITF2357 or pemetrexed alone (Figure 5C). A similar
rescue of cell viability after combined treatment was
also observed when cells were exposed to 3MA, an
early-stage autophagy inhibitor (Additional file 3: Figure
S3D). As exposure to 3MA represents a condition that at
high concentration can paradoxically induce autophagy
by inhibiting class I PI3-kinase [48], the effect of 3MA
on Akt/mTOR pathway has been investigated in H1299
cells. Western blot analysis demonstrated that phos-
phorylation of either Akt at Ser473 or mTOR was not
affected by exposure to 3MA (Additional file 3: Figure
S3E).
Taken together, these findings strongly indicate that
the combination of pemetrexed followed by ITF2357activates an autophagic flux, which, in turn, results in
apoptosis induction and overall loss of cell viability.
ITF2357 enhances pemetrexed cytotoxicity in
patient-derived LCSC in vitro and NSCLC models in vivo
The sensitivity to ITF2357 and pemetrexed alone or in
combination and the modulation of markers of apoptosis
and autophagy were also evaluated in patient-derived
LCSC models in vitro. As reported in Additional file 5:
Figure S5A, ITF2357 exposure dose-dependently re-
duced cell viability in four LCSC cell lines tested, al-
though with different IC50 (0.1 and 0.5 μM in the highly
sensitive LCSC136 and LCSC36 lines, as opposed to 5
and >5 μM in the relatively more resistant LCSC18 and
LCSC143 cell lines, respectively). Increased histone H3
acetylation and PARP activation were observed in the
LCSC136 cell line after exposure to ITF2357 (Additional
file 3: Figure S3B). Consistent with the findings de-
scribed above in NSCLC cell lines, ITF2357 decreased TS
protein expression in the LCSC143 line (Figure 6A) and
synergistically inhibited in vitro cell growth, when admin-
istered after pemetrexed exposure (Figure 6B,C). Com-
bined treatment induced both apoptosis and autophagy,
as evidenced by PARP cleavage, increased LC3B-II
levels, and decreased p62/SQSTM1 protein expression
(Figure 6A).
Finally, we investigated the in vivo efficacy of ITF2357
and pemetrexed alone or in combination. To this purpose,
established H1650 xenografts in nude mice were treated
with vehicle, pemetrexed (1000 mg/kg/weekly), ITF2357
(100 mg/kg/daily for 4 days), or sequential pemetrexed/
ITF2357 (weekly pemetrexed followed by daily ITF2357 for
4 days, starting 24 h after pemetrexed administration). As
reported in Figure 6D, pemetrexed and ITF2357 had min-
imal effect on mice survival. In contrast, sequential peme-
trexed/ITF2357 administration inhibited tumor growth and
prolonged mice survival, as compared to single agent ad-
ministration. Similar to in vitro experiments, qRT-PCR ana-
lyses from tumor xenograft specimens evidenced a 2-fold
increase and a 2-fold decrease in the median of TS mRNA
relative to control after treatment with pemetrexed and
ITF2357, respectively, while similar TS expression was
Figure 4 (See legend on next page.)
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Figure 4 Combination treatment with pemetrexed followed by ITF2357 leads to autophagy induction in human NSCLC cell lines.
(A) Flow cytometric analysis of acid vesicular organelles (AVOs) by acridine orange staining in H1299 and A549 cells exposed to pemetrexed
(Pem, 0.1 μM) or ITF2357 (from 0.1 to 1 μM) alone or in combination (24 h pemetrexed followed by 48 h ITF2357). The percentage of cells with
prominent red fluorescence, indicative of AVOs formation, is shown. Each panel is representative of three independent experiments with
comparable results. Representative images of fluorescence microscopy in H1299 cells stably transfected with EGFP-LC3B vector (H1299/EGFP-LC3)
(B), and in H1299 cells stably transfected with ptf-LC3B vector (H1299/ptf-LC3) (C) exposed to pemetrexed (0.1 μM) or ITF2357 (1 μM) alone or in
combination (24 h pemetrexed followed by 48 h ITF2357). (D) Quantification of cells positive for EGFP (green) and mRFP (red) autophagosomal
structures treated as indicated in B and C. The results represent the mean ± SEM of three independent experiments. (E) Western blot analysis of p62/
SQTSM1, Beclin1, ATG7, LC3B-I/II protein expression in H1299 cells treated as reported in (A). HSP72/73 is shown as loading and transferring control.
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differences did not reach statistical significance (data not
shown).
Similar results were also obtained in H1299 xeno-
grafts, with 35% inhibition of tumor growth with com-
bined treatment, as compared to about 15% with singleFigure 5 Induction of autophagy is essential for cytotoxic effect of pe
Analysis of (A) acid vesicular organelles (AVOs) by acridine orange, (B) apo
in H1299 cells stably expressing control short hairpin RNA (H1299) or short
against ATG7 (H1299/siATG7) and exposed to pemetrexed (Pem, 0.1 μM) o
followed by 48 h ITF2357) in absence or presence of the pan-caspase inhibtreatments, at day 35 after tumor cell injection (data not
shown).
Discussion
The present study sought to understand whether the
modulation of TS expression induced by ITF2357-memetrexed followed by ITF2357 in human NSCLC cell lines.
ptotic cells by AnnexinV/PI staining, and (C) cell viability by MTT assay
hairpin RNA directed against Beclin1 (H1299 shBeclin1) or siRNA
r ITF2357 (1 μM) alone or in combination treatment (24 h pemetrexed
itor zVAD (50 μM).
Figure 6 Growth-inhibitory and molecular effects of sequential ITF2357/pemetrexed in LCSC in vitro and in vivo xenografts models.
(A) Western blot analysis of TS, p62/SQTSM1, LC3B-I/II and PARP proteins in total cell lysates from LCSC143 cell line exposed to pemetrexed (PEM,
0.1 μM) or ITF2357 (1 μM) alone or in combination (24 h pemetrexed followed by 48 h ITF2357). HSP72/73 expression was used as loading and
transferring control. (B) Analysis of cell viability by CellTiter-Glo assay and (C) drugs interaction evaluated on the basis of the Combination Index, which
is plotted against fractional growth inhibition in LCSC143 line treated with ITF2357 and pemetrexed (drug ratio 1:1) alone or in combination. Treatment
with pemetrexed for 24 h was followed by treatment with ITF2357 for 48 h. (●, ITF2357; ■ , pemetrexed;▲, combination) The results are reported as
“viability of ITF2357-treated cells/viability of untreated cells” × 100 and represent the mean ± SD of three independent experiments. (D) In vivo
response of H1650 xenograft to pemetrexed (1000 mg/kg/weekly) or ITF2357 (100 mg/kg day for 4 days) alone or in combination (pemetrexed, 1000
mg/kg/weekly followed by ITF2357, 100 mg/kg/day for 4 days).
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NSCLC and LCSC-derived cell lines to pemetrexed. We
found that the sequence of drug administration is critical in
determining a synergistic interaction between pemetrexed
and ITF2357 in both models. In particular, simultaneous
treatment with the two drugs resulted in antagonistic ef-
fects, and ITF2357 followed by pemetrexed showed a
synergistic effect only in some cell lines. On the contrary, a
sequence-dependent, highly synergistic potentiation ofpemetrexed activity was observed when ITF2357 was ad-
ministered after pemetrexed exposure. Notably, such syner-
gistic effect was evident in models of both adenocarcinoma
and squamous cell carcinoma of the lung, a histologic sub-
type that is currently considered to be clinically resistant to
pemetrexed [4], including patient-derived LCSC.
TS, one of the intracellular targets of pemetrexed, has
been shown to be downmodulated by HDACi [23],
through the Rb-E2F1-p21 axis, and hence may have a
Del Bufalo et al. Molecular Cancer 2014, 13:230 Page 13 of 16
http://www.molecular-cancer.com/content/13/1/230close association with pemetrexed efficacy. Compounds
that modulate TS expression can potentially influence
the activity of TS inhibitors and enhance the cytotoxicity
of several drugs [49,50]. We found that both TS mRNA
and protein expression were downregulated by ITF2357
when administered alone or in combination with peme-
trexed. Although these findings are consistent with our
mechanistic hypothesis, the fact that TS downregulation
by siRNA further enhanced apoptosis induction ob-
served with single and combined pemetrexed treatment
raises the possibility that other sites of pemetrexed ac-
tion, such as aminoimidazolecarboxamide ribonucleotide
formyltransferase, or glycinamide ribonucleotide trans-
formylase, may also play a role in the observed cytotoxic
interaction between pemetrexed and ITF2357.
Our study shows that the mechanism of cell death in-
duced by the combined treatment involves both autoph-
agy and apoptosis, and provides an interesting link
between these two pathways and loss of cell viability. In
particular, combined treatment induced a canonical mo-
lecular autophagic pathway dependent on Beclin1 and
ATG7, involved in the nucleation and conjugation ma-
chinery, respectively. This process proceeds unimpeded,
with the ultimate fusion between autophagosomes and
lysosomes, resulting in degradation of the cargo of the
autophagosomes by lysosomal hydrolases [30,32]. Accu-
mulating evidence reveals that autophagy and apoptosis
can cooperate, antagonize or assist each other, thus
differentially influencing cell fate [45-47,51]. Using both
pharmacologic and genetic approaches, we showed that
these two mechanisms might act in concert to induce
cell death upon sequential pemetrexed/ITF2357 treat-
ment. In particular, when autophagy was repressed by
Beclin1 or ATG7 knockdown, a decreased rate of apop-
tosis was detected in cells exposed to the drug combin-
ation. These results indicate that, in this specific context,
autophagy positively controls apoptosis induction. Not-
ably, genetic and pharmacological inhibition of late
stages of autophagy, using a siRNA against LAMP2 or
Chloroquine respectively, only marginally affected the
effects of sequential ITF2357/pemetrexed on cell viabil-
ity (data not shown). Conversely, the pan-caspase inhibi-
tor zVAD did reduce apoptosis induction, but had little
if any effect on autophagic markers and cell viability. In
this context, it is important to note that the experimen-
tal data from viability measurements are not a function
of sole caspases activation. On the other hand in many
assays generally used for viability measurements the per-
centage cell viability could be significantly overestimated
or underrated when the cells are committed to an
autophagic pathway.
Overall, these results indicate that in NSCLC models
sequential pemetrexed/ITF2357 causes a toxic form of
autophagy, with consequent activation of the apoptoticprogram, which can lead to caspase-dependent apop-
tosis. From a mechanistic standpoint, we can speculate
that the increased formation of acidic lysosomes, as
the final end product of the autophagic flux, may lead to
the release of active cathepsins or calpain proteases into
the cytosol, where proapoptotic proteins such as BID
can then be cleaved/activated [52]. It is also possible that
Beclin1 and ATG5, which are required for the formation
of autophagosomes, enhance susceptibility to apoptotic
stimuli upon cleavage by proteases. Truncated proteins
might translocate to mitochondria, and sensitize cells to
apoptosis, possibly through the release of pro-apoptotic
factors [53,54]. A pro-apoptotic function for ATG12, the
conjugation partner of ATG5, has been recently identi-
fied, being ATG12 required for caspase activation in
response to a variety of apoptotic stresses [55]. The mo-
lecular mechanisms underlying the apoptotic function of
the non-conjugated forms of ATG5 and ATG12 might
be similar, as both proteins were shown to interact with
anti-apoptotic members of the BCL2 family [54,55].
Autophagy can also contribute to the induction of apop-
tosis activated by intrinsic stress signals through recruit-
ment of caspase-8 to autophagosomes and consequent
activation [56]. Finally, although protein degradation by
autophagy is considered to be largely non-selective, an in-
teresting concept for the direct regulation of apoptosis by
autophagy is the selective targeting of apoptotic proteins
for autophagic degradation. In this way, autophagy could
shift the balance between anti- and pro-apoptotic factors,
leading to initiation or inhibition of apoptosis [47,55,57].
In vivo experiments in nude mice provide a proof of the
principle that a sequential schedule of pemetrexed followed
by ITF2357 may indeed be developed for clinical testing, as
the combination was able to substantially inhibit tumor
growth and increase mice survival, with no increased tox-
icity. Such a sequential, intermittent, schedule of adminis-
tration would have the advantage of maximizing the
synergistic anti-tumor interactions between the two drugs,
as indicated by in vitro modeling of different administra-
tion schedules, while simultaneously avoiding toxicities re-
lated to continuous HDACi administration [58].
Conclusion
Our data indicate that combined treatment with peme-
trexed followed by the HDACi ITF2357 has strikingly
synergistic anti-tumor activity in NSCLC models. In par-
ticular, sequential administration of pemetrexed followed
by ITF2357 was crucial in inducing growth-inhibitory
synergism between the two drugs in all NSCLC models
tested, at least in part due to ITF2357 ability to down-
regulate TS expression. Interestingly, while inhibition of
initiation and autophagosome elongation blocked both
AVOs formation and apoptosis induction, a pan-caspase
inhibitor had no effect on AVOs accumulation induced by
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a hierarchical activation of an autophagy program, which
in turn results in the activation of caspase-dependent
apoptosis, both of which contribute to loss of cell viability.
Sequential pemetrexed followed by ITF2357 was also
feasible and effective in xenograft models of NSCLC,
supporting the possibility to develop such rational,
mechanism-based combination schedule for the treat-
ment of advanced NSCLC in the clinical setting.
Additional files
Additional file 1: Figure S1. (A) Analysis of cell viability by MTT assay
in the indicated NSCLC cell lines treated with different schedules of
ITF2357 and Pemetrexed (drug ratio 1:1). Cells were treated with each
drug, either alone or in combination, as follows: 72 h ITF2357 and
Pemetrexed, simultaneously (ITF2357 + PEM); 24 h ITF2357 followed by
48h Pemetrexed (ITF2357 -> PEM). The results are reported as “viability of
drug-treated cells/viability of untreated cells” × 100 and represent the
mean ± SD of three independent experiments. (■, Pemetrexed; ●,
ITF2357; ▲, combination). (B) Interaction between Pemetrexed and
ITF2357 treatment evaluated on the basis of the combination index (CI),
which is plotted against fractional growth inhibition. Data are means of
triplicates from experiments that were repeated three times.
Additional file 2: Figure S2. (A) Analysis of cell viability by MTT assay
in the indicated NSCLC cell lines treated with ITF2357 and Pemetrexed
(drug ratio 1:1) alone or in combination (24 h Pemetrexed followed by 48 h
ITF2357). (■, Pemetrexed; ●, ITF2357;▲, combination). (B) Interaction
between Pemetrexed and ITF2357 treatment evaluated on the basis of the
combination index (CI), which is plotted against fractional growth inhibition.
Cells were treated as reported in (A). Data are means of triplicates from
experiments that were repeated three times. (C) Analysis of Active caspase-
3 form by cytofluorimetric analysis in A549 cells exposed to pemetrexed
(Pem, 0.1 μM) or ITF2357 (1 μM) alone or in combination treatment
(24h pemetrexed followed by 48 h ITF2357) in absence or presence of the
pan-caspase inhibitor zVAD (50 μM).
Additional file 3: Figure S3. (A) TS mRNA expression by quantitative
RT-PCR in H1299 cells transiently transfected with control RNA interference
(H1299/Cont), or RNA interference directed against TS (H1299/siTS). Results are
presented as the mean ± SD of 2 independent experiments. p values were
calculated between control and treated cells (*p<0.05). Western blot analysis
of Beclin1 (B) and ATG7 (C) protein expression in total cell lysates from H1299
cells stably expressing control short hairpin RNA (H1299 shCont) or short
hairpin RNA directed against Beclin1 (H1299 shBeclin1) or ATG7 (H1299/
siATG7). HSP72/73 expression was used as loading and transferring control.
Western blots representative of two independent experiments with similar
results are shown. (D) Analysis of viable cells evaluated by CellTiter-Glo, in
HI299 exposed to Pemetrexed (PEM, 0.1 μM) or ITF2357 (1 μM) alone or in
combined treatment (24 h Pemetrexed followed by 48 h ITF2357) in absence
or presence of 3MA (1 mM). (E) Western blot analysis of phosphorylated forms
of AKT and mTOR proteins in H1299 cells in absence or presence of 3MA
(1 mM) for 48 h. HSP72/73 expression was used as loading and transferring
control. Western blots representative of two independent experiments with
similar results are shown. (F) Cytofluorimetric analysis of Active caspase-3
form in H1299 and H1299/shBeclin1 cells exposed to pemetrexed (Pem, 0.1
μM) or ITF2357 (1 μM) alone or in combination
treatment (24 h pemetrexed followed by 48 h ITF2357).
Additional file 4: Figure S4. (A) Representative images of
autophagosomal structures by fluorescence microscopy in H1299 cells
stably transfected with EGFP-LC3B vector (H1299/EGFP-LC3), and in H1299
cells stably transfected with ptf-LC3B vector (H1299/ptf-LC3) exposed to
chloroquine (CQ, 25 mM) for 24 h. As GFP but not mRFP fluorescence is lost
in acidic compartments, mRFP-GFP-LC3B labels non-acidic autophagosomes
as yellow fluorescence (positive for both green and red) but acidic
autophagolysosomes as red fluorescence only. (B) Western blot analysis of
p62/SQTSM1 and LC3B-I/II protein expression in H1299/shBeclin1 cellstreated with pemetrexed (Pem, 0.1 μM) or ITF2357 (0.5 μM) alone or in
combination (24 h pemetrexed followed by 24 h ITF2357) in absence or
presence of Chloroquine (CQ, 5 μM) for 18 h. β-actin is shown as loading
and transferring control. Western blots representative of two independent
experiments with similar results are shown.
Additional file 5: Figure S5. (A) Analysis of cell viability in the
indicated LCSC lines treated with ITF2357 for 72 h. The results are
reported as “viability of treated cells/viability of untreated cells” × 100
and represent the mean ± SD of three independent experiments. (B)
Western blot analysis of acetylated histone H3 (Ac-H3) and PARP protein
expression in total cell lysates from LCSC136 cell line treated with
increasing concentration of ITF2357 for 72 h. HSP72/73 expression was
used as loading and transferring control. Western blots representative of
two independent experiments with similar results are shown.
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